HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DCZ0358

Also Known As:

5-(benzo(d) (1,3)dioxol-5-yl)-3,9,10-trimethoxy-2,3-dihydrooxazolo (2,3-a)isoquinolin- 4-ium chloride

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - DCZ0358: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - DCZ0358: 3

Experts

1.	Bu, Wenxuan: 1 article (01/2018)
2.	Chang, Shuaikang: 1 article (01/2018)
3.	Gao, Lu: 1 article (01/2018)
4.	Hu, Liangning: 1 article (01/2018)
5.	Lan, Xiucai: 1 article (01/2018)
6.	Li, Bo: 1 article (01/2018)
7.	Liu, Peng: 1 article (01/2018)
8.	Shi, Jumei: 1 article (01/2018)
9.	Sun, Xi: 1 article (01/2018)
10.	Tao, Yi: 1 article (01/2018)

Related Diseases

1.	Multiple Myeloma 01/01/2018 - "Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment." 02/25/2023 - "A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway."
2.	Mitochondrial Diseases (Mitochondrial Disease) 12/01/2023 - "Furthermore, DCZ0358 enhanced mitochondrial membrane potential depolarization, promoted mitochondrial permeability transport pore openness, increased cytoplastic Ca2+ levels and decreased intracellular adenosine triphosphate production, which led to mitochondrial dysfunction. "
3.	Neoplasms (Cancer) 12/01/2023 - "Above results demonstrated anti-tumor molecular mechanism of DCZ0358 in DLBCL cells and highlighted the ROS/JNK/DNA damage pathway as a potential target in therapies, which have implications for the development of more effective clinical treatments for DLBCL." 12/01/2023 - "Most importantly, DCZ0358 exhibited synergistic anti-tumor effects when combined with etoposide, a common clinical anti-DLBCL drug, both in vitro and certainly in vivo. "

Related Drugs and Biologics

1.	Etoposide (VP 16)
2.	Alkaloids
3.	Adenosine Triphosphate (ATP)
4.	Mechanistic Target of Rapamycin Complex 1
5.	Bortezomib (Velcade)

Related Therapies and Procedures

1.	Therapeutics